Human papillomavirus (HPV) genotypes and HPV16 variants and risk of adenocarcinoma and squamous cell carcinoma of the cervix

Tornesello, Maria Lina; Losito, Simona; Benincasa, Giulio; Fulciniti, Franco; Botti, Gerardo; Greggi, Stefano; Buonaguro, Luigi; Buonaguro, Franco M.

doi:10.1016/j.ygyno.2010.12.005

Cited by 85 publications

(84 citation statements)

References 73 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…HPV16 infections circulating in the general Danish population were shown to be predominantly of the EUR variant lineage (97%), as seen in a previous population-based cohort study in France (95%; 23) and among series of HPV16-positive women referred for cervical abnormalities and/or diagnosed with cervical cancer in Northern Europe (90%-100%) (22,26,27), (20,(28)(29)(30), reviewed in (31). This confirms findings that non-EUR (AA, As, AFR1, and AFR2) are far less frequent in Northern Europe than in Asia, Africa, or the Americas (20), reviewed in (31), and less common even than in Southern Europe, where 13%-36% of HPV16-positive women referred for colposcopy and/or diagnosed with cervical cancer have been reported as infected with non-EUR lineages (20-22, 32, 33).…”

Section: Discussionmentioning

confidence: 57%

“…However, the definition of HPV16 persistence was less well defined than in the present study (i.e., persistent at 2 years) and 95% confidence intervals remain compatible with the present findings. EUR-350T accounted for 62% of all EUR lineages at baseline in Denmark, which compares with 52% in the French study (23) and with 45% among European women with normal cytology included in a recent literature review of cross-sectional studies (31).…”

Section: Discussionmentioning

confidence: 79%

See 1 more Smart Citation

Risks for Persistence and Progression by Human Papillomavirus Type 16 Variant Lineages Among a Population-Based Sample of Danish Women

Gheit

Cornet

Clifford

et al. 2011

Cancer Epidemiology, Biomarkers &Amp; Prevention

View full text Add to dashboard Cite

Background: Little is known about factors determining HPV16 persistence and progression, but several studies have suggested that genetic variants may play a role.Methods: HPV16-positive women with normal cytology in a large Danish cohort were reassessed for HPV16 status at 2 years and followed-up for cervical intraepithelial neoplasia 3 or worse (CIN3þ) over 11 years through linkage with a national pathology database. Relative risks for clearance, persistence, and progression were compared with different HPV16 variant lineages based upon E6 gene sequencing.Results: Sixty-two (23.7%) of 261 HPV16 infections were persistent at 2 years, and 32 (51.6%) persistent infections progressed to CIN3þ. The majority of baseline infections belonged to the European lineage (97.3%), with EUR-350T and EUR-350G accounting for 61.3% and 36.0% of infections, respectively. At two years, the proportion of HPV16 infections that persisted was significantly higher for EUR-350T (28.2%) than EUR-350G (15.9%) variants (odds ratio ¼ 2.06, 95% CI, 1.04-4.25). This increased risk for persistence was consistent both in the absence (OR ¼ 2.16, 95% CI, 0.84-6.26) or presence (OR ¼ 1.89, 95% CI, 0.76-5.15) of progression to CIN3þ. Among persistent HPV16 infections, there was no significant difference in risk of progression to CIN3þ between EUR-350T and EUR-350G sub-lineages, which were both associated with a substantial absolute risk (>50%) of CIN3þ.Conclusions: Significant differences in risk for persistence exist between the HPV16 variants that predominate in Europe.Impact: Understanding the genetic basis of HPV16 persistence and carcinogenicity may help unravel important interactions between HPV16 and the host immune system. Cancer Epidemiol Biomarkers Prev; 20(7); 1315-21. Ó2011 AACR.

show abstract

Section: Discussionmentioning

confidence: 57%

Section: Discussionmentioning

confidence: 79%

Risks for Persistence and Progression by Human Papillomavirus Type 16 Variant Lineages Among a Population-Based Sample of Danish Women

Gheit

Cornet

Clifford

et al. 2011

Cancer Epidemiology, Biomarkers &Amp; Prevention

View full text Add to dashboard Cite

show abstract

“…Samples were stored at À20°C until further processing. All the samples were analysed for the presence of high-risk HPV types only (16,18,31,33,35,39,45,51,52,56,58,59, and 68). The recommended cut-off of 1.0 pg/ml relative light units (RLU) was used to classify a specimen as positive or negative.…”

Section: Hc2 Testingmentioning

confidence: 99%

“…Finally, HC2-negative CCs were tested for the presence of high-risk HPV E7 DNA using a sensitive E7 multiplex PCR, enabling the detection of 14 high-risk HPV types (16,18,31,33,35,39,45, 51, 52, 56, 58, 59, 66, 68).…”

Section: Dna Detection and Genotypingmentioning

confidence: 99%

HPV‐negative carcinoma of the uterine cervix: a distinct type of cervical cancer with poor prognosis

Rodríguez‐Carunchio

Soveral

Steenbergen

et al. 2014

BJOG

178

173

View full text Add to dashboard Cite

Objective Using highly sensitive polymerase chain reaction (PCR) techniques, we reanalysed all cervical carcinomas (CCs) found to be human papillomavirus (HPV)-negative by Hybrid Capture 2 (HC2) to determine the prevalence of true HPV-negativity. We also evaluated the characteristics of the patients with tumours with confirmed HPV-negativity.Design Observational study.Setting Barcelona, Spain.Population A cohort of 136 women with CC (32 adenocarcinomas, 104 squamous cell carcinomas) who had pre-treatment HC2 testing.Methods All negative cases were reanalysed and genotyped for HPV using three PCR assays (SPF10, GP5+/6+ and E7-specific assay).Main outcome measures Percentage of confirmed HPV-negative and HPV-positive tumours. Clinicopathological features and disease-free survival (DFS) and overall survival (OS) of both groups.Results Fourteen of 136 women (10.2%) were negative for HPV by HC2. After reanalysis by PCR-based techniques only 8/136 (5.8%) tumours were confirmed as HPV-negative, whereas in six cases different HPVs were identified [HPV-11, À16 (two tumours), À18, À45, and À68]. Confirmed HPV-negativity was more frequent in adenocarcinomas than in squamous cell carcinomas (5/32, 15.6% versus 3/104, 2.9%, respectively; P = 0.017). Patients with CCs with confirmed HPV-negativity had significantly worse DFS than women with HPV-positive tumours [51.9 months (95% CI 12.2-91.7 months) versus 109.9 months (95% CI 98.2-121.5 months); P = 0.010]. In the multivariate analysis HPV-negativity and International Federation of Gynecology and Obstetrics (FIGO) staging were associated with increased risk of progression and mortality.Conclusions An HC2-negative result is an uncommon finding in women with CC, but in almost half of these cases HPVs are identified by more sensitive techniques. CCs with confirmed HPV-negativity are more frequently adenocarcinomas, and seem to be associated with worse DFS.

show abstract

“…The association noted between the Asian-American variant of HPV type 16, which is known to have increased susceptibility to estrogenic effects, and increased incidence in obese individuals provides additional support for this linkage. 10 A further link between endocervical and squamous carcinogenesis exists. About 50% of endocervical tumors have a coexisting squamous lesion present.…”

Section: Endocervical Neoplasia: General Featuresmentioning

confidence: 99%

Practical issues related to uterine pathology: in situ and invasive cervical glandular lesions and their benign mimics: emphasis on cytology–histology correlation and interpretive pitfalls

Wilbur

2016

Modern Pathology

View full text Add to dashboard Cite

In situ and invasive neoplastic glandular lesions of the uterine have cytologic correlates that must be distinguished from a variety of benign and reactive conditions. Careful study of the cytologic features allows discrimination in the majority of cases; however, the designation of 'atypical glandular cells' is reserved for equivocal cases that cannot be readily resolved. In this article, the cytologic features of endocervical adenocarcinoma in situ and invasive endocervical adenocarcinoma will be presented, highlighting their correlation to the well-known histologic features. Variants of the usual type of endocervical neoplasms that have important clinical and differential diagnostic features, including mucinous adenocarcinoma and clear-cell carcinoma, will be discussed. There are a number of common cytologic mimics of endocervical neoplasms, including tubal metaplasia, directly sampled (abraded) endometrium, and high-grade squamous intraepithelial lesion involving endocervical glands. The cytologic features of these entities and their differentiation from endocervical neoplasia will be explored. Finally, the role of ancillary studies such as human papillomavirus testing in the management of glandular lesions of the cervix will be integrated into the discussion.

show abstract

Human papillomavirus (HPV) genotypes and HPV16 variants and risk of adenocarcinoma and squamous cell carcinoma of the cervix

Cited by 85 publications

References 73 publications

Risks for Persistence and Progression by Human Papillomavirus Type 16 Variant Lineages Among a Population-Based Sample of Danish Women

Risks for Persistence and Progression by Human Papillomavirus Type 16 Variant Lineages Among a Population-Based Sample of Danish Women

HPV‐negative carcinoma of the uterine cervix: a distinct type of cervical cancer with poor prognosis

Practical issues related to uterine pathology: in situ and invasive cervical glandular lesions and their benign mimics: emphasis on cytology–histology correlation and interpretive pitfalls

Contact Info

Product

Resources

About